A prognostic and therapeutic signature for malignant melanoma

摘要

A method of predicting the course of the disease in a patient having a malignant melanoma, the method comprises determining in melanoma cells comprised in a sample obtained from said malignant melanoma the presence or quantity of at least five biomarkers selected from the group consisting of MTAP, PTEN, Bax, Bcl-X, ß-catenin, CD20, Cox-2, CD49d and MLH1, where the absence or decreased amount of MTAP and ß-catenin and / or the presence or increased amount of PTEN, Bax, Bcl-X, CD20, Cox-2, CD49d, and MLH1 are associated with a disadvantageous course of the disease.